CDK8 Inhibition Increases E2F1 Transcriptional Activity and Promotes STAT3-Dependent Suppression of Mcl-1 in Triple-Negative Breast Cancer Cell Line MDA-MB-468
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27020897 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Sandra Do und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA 95211, USA. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, E2F1 Transcription Factor, Triple Negative Breast Neoplasms, Myeloid Cell Leukemia Sequence 1 Protein. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jie Du Center for Innovation and Excellence for Drug Development.
Abstract (Originalsprache)
The targeting of cyclin dependent kinase 8 (CDK8) as a potential strategy for cancer treatment has been of interest since the identification of CDK8 as an oncogene product. In this report, we communicate the results of our continuing investigation into the effects of CDK8 inhibitor on triple-negative breast cancer cell line MDA-MB-468. Here, we demonstrate that inhibition of CDK8 decreases phosphorylation of CDK8 substrates E2 promoter binding factor 1 (E2F1) at serine 375 and signal transducer and activator of transcription 3 (STAT3) at serine 727 in these cells. Additionally, luciferase expression was increased in E2F1-responsive luciferase plasmid-transfected cells. Expression of E2F1 transcription target, the proapoptotic protein p73, was increased, and expression of antiapoptotic protein myeloid cell leukemia sequence 1 (Mcl-1) was decreased in CDK8 inhibitor-treated cells. We also demonstrate that knockdown of STAT3 or disruption of STAT3 function in MDA-MB-468 cells opposes the effects of CDK8 inhibition on Mcl-1. Together, these results suggest that CDK8 inhibitor treatment can modulate the expression of apoptosis-related proteins p73 and Mcl-1 and continues to highlight the potential cooperative effects of E2F1 and STAT3 in the activity of CDK8 inhibitor against MDA-MB-468 triple-negative breast cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA 95211, USA.
ORCID-Profile: Jensen M Spear
Förderung
- Jie Du Center for Innovation and Excellence for Drug Development
Zitieren
APA
Do, S., Li, S., Xiong, R., Spear, J. M., Lu, Z., Chan, W. K., & Russu, W. A. (2026). CDK8 Inhibition Increases E2F1 Transcriptional Activity and Promotes STAT3-Dependent Suppression of Mcl-1 in Triple-Negative Breast Cancer Cell Line MDA-MB-468. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020897
Vancouver
Do S, Li S, Xiong R, Spear JM, Lu Z, Chan WK, et al. CDK8 Inhibition Increases E2F1 Transcriptional Activity and Promotes STAT3-Dependent Suppression of Mcl-1 in Triple-Negative Breast Cancer Cell Line MDA-MB-468. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020897
BibTeX
@article{Do2026,
author = {Do, Sandra and Li, Shengxi and Xiong, Rui and Spear, Jensen M and Lu, Zhixin and Chan, William K and Russu, Wade A},
title = {CDK8 Inhibition Increases E2F1 Transcriptional Activity and Promotes STAT3-Dependent Suppression of Mcl-1 in Triple-Negative Breast Cancer Cell Line MDA-MB-468},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27020897}
}
EUVIMED